Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma (CANDLE trial)

被引：0
|
作者：
Ishida, Tadao
Ozaki, Shuji
Kimura, Hideo
Kubo, Koumei
Sunami, Kazutaka
Takezako, Naoki
Fujita, Hiroyuki
Hayashi, Toshiaki
Kiguchi, Toru
Kobayashi, Takeshi
Yamamoto, Satoshi
Takamatsu, Hiroyuki
Kosugi, Hiroshi
Ohta, Kensuke
Sakai, Rika
Handa, Hiroshi
Hisatomi, Takashi
Abe, Yu
Sasaki, Ko
Omoto, Eijiro
Murakami, Hirokazu
Shimizu, Kazuyuki
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3121
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Interim Analysis of Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma.
    Ishida, Tadao
    Kimura, Hideo
    Kubo, Koumei
    Sunami, Kazutaka
    Ozaki, Shuji
    Takezako, Naoki
    Handa, Hiroshi
    Kosugi, Hiroshi
    Murakami, Hirokazu
    Shimizu, Kazuyuki
    BLOOD, 2015, 126 (23)
  • [2] Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma
    Ishida, Tadao
    Kimura, Hideo
    Ozaki, Shuji
    Kubo, Koumei
    Sunami, Kazutaka
    Takezako, Naoki
    Fujita, Hiroyuki
    Hayashi, Toshiaki
    Kiguchi, Toru
    Ohashi, Kazuteru
    Yamamoto, Satoshi
    Takamatsu, Hiroyuki
    Kosugi, Hiroshi
    Ohta, Kensuke
    Sakai, Rika
    Handa, Hiroshi
    Kondo, Seiji
    Abe, Yu
    Omoto, Eijiro
    Mitani, Kinuko
    Morita, Satoshi
    Murakami, Hirokazu
    Shimizu, Kazuyuki
    ANNALS OF HEMATOLOGY, 2020, 99 (05) : 1063 - 1072
  • [3] Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma
    Tadao Ishida
    Hideo Kimura
    Shuji Ozaki
    Koumei Kubo
    Kazutaka Sunami
    Naoki Takezako
    Hiroyuki Fujita
    Toshiaki Hayashi
    Toru Kiguchi
    Kazuteru Ohashi
    Satoshi Yamamoto
    Hiroyuki Takamatsu
    Hiroshi Kosugi
    Kensuke Ohta
    Rika Sakai
    Hiroshi Handa
    Seiji Kondo
    Yu Abe
    Eijiro Omoto
    Kinuko Mitani
    Satoshi Morita
    Hirokazu Murakami
    Kazuyuki Shimizu
    Annals of Hematology, 2020, 99 : 1063 - 1072
  • [4] Randomised, Phase 3 Study of Bortezomib, Lenalidomide and Dexamethasone Followed by Ciltacabtagene Autoleucel Versus Bortezomib, Lenalidomide and Dexamethasone Followed by Lenalidomide and Dexamethasone Maintenance in Patients With Newly Diagnosed Multiple Myeloma Not Intended for Transplant: CARTITUDE-5
    Dytfeld, Dominik
    Dhakal, Binod
    Agha, Mounzer
    Manier, Salomon
    Delforge, Michel
    Kuppens, Steven
    Afifi, Salma
    Deraedt, William
    Taraseviciute-Morris, Agne
    Schecter, Jordan M.
    Gilbert, Jane
    Yalniz, Fevzi
    Florendo, Erika
    Pacaud, Lida
    Hungria, Vania
    Usmani, Saad Z.
    Mateos, Maria-Victoria
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 122 - 123
  • [5] Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma
    Reiko Isa
    Nobuhiko Uoshima
    Ryoichi Takahashi
    Sonoko Nakano-Akamatsu
    Eri Kawata
    Hiroto Kaneko
    Kazuho Shimura
    Yuri Kamitsuji
    Tomoko Takimoto-Shimomura
    Shinsuke Mizutani
    Yoshiaki Chinen
    Muneo Ohshiro
    Takahiro Fujino
    Yuka Kawaji
    Hitoji Uchiyama
    Nana Sasaki
    Taku Tsukamoto
    Yuji Shimura
    Tsutomu Kobayashi
    Masafumi Taniwaki
    Junya Kuroda
    Annals of Hematology, 2020, 99 : 137 - 145
  • [6] Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma
    Isa, Reiko
    Uoshima, Nobuhiko
    Takahashi, Ryoichi
    Nakano-Akamatsu, Sonoko
    Kawata, Eri
    Kaneko, Hiroto
    Shimura, Kazuho
    Kamitsuji, Yuri
    Takimoto-Shimomura, Tomoko
    Mizutani, Shinsuke
    Chinen, Yoshiaki
    Ohshiro, Muneo
    Fujino, Takahiro
    Kawaji, Yuka
    Uchiyama, Hitoji
    Sasaki, Nana
    Tsukamoto, Taku
    Shimura, Yuji
    Kobayashi, Tsutomu
    Taniwaki, Masafumi
    Kuroda, Junya
    ANNALS OF HEMATOLOGY, 2020, 99 (01) : 137 - 145
  • [7] Lenalidomide - prednisone induction followed by lenalidomide - melphalan - prednisone consolidation and lenalidomide - prednisone maintenance in newly diagnosed elderly unfit myeloma patients
    Falco, P.
    Cavallo, F.
    Larocca, A.
    Rossi, D.
    Guglielmelli, T.
    Rocci, A.
    Grasso, M.
    Siez, M. L. M.
    De Paoli, L.
    Oliva, S.
    Molica, S.
    Mina, R.
    Gay, F.
    Benevolo, G.
    Musto, P.
    Omede, P.
    Freilone, R.
    Bringhen, S.
    Carella, A. M.
    Gaidano, G.
    Boccadoro, M.
    Palumbo, A.
    LEUKEMIA, 2013, 27 (03) : 695 - 701
  • [8] Lenalidomide−prednisone induction followed by lenalidomide−melphalan−prednisone consolidation and lenalidomide−prednisone maintenance in newly diagnosed elderly unfit myeloma patients
    P Falco
    F Cavallo
    A Larocca
    D Rossi
    T Guglielmelli
    A Rocci
    M Grasso
    M L M Siez
    L De Paoli
    S Oliva
    S Molica
    R Mina
    F Gay
    G Benevolo
    P Musto
    P Omedè
    R Freilone
    S Bringhen
    A M Carella
    G Gaidano
    M Boccadoro
    A Palumbo
    Leukemia, 2013, 27 : 695 - 701
  • [9] Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
    Voorhees, Peter M.
    Kaufman, Jonathan L.
    Laubach, Jacob
    Sborov, Douglas W.
    Reeves, Brandi
    Rodriguez, Cesar
    Chari, Ajai
    Silbermann, Rebecca
    Costa, Luciano J.
    Anderson, Larry D., Jr.
    Nathwani, Nitya
    Shah, Nina
    Efebera, Yvonne A.
    Holstein, Sarah A.
    Costello, Caitlin
    Jakubowiak, Andrzej
    Wildes, Tanya M.
    Orlowski, Robert Z.
    Shain, Kenneth H.
    Cowan, Andrew J.
    Murphy, Sean
    Lutska, Yana
    Pei, Huiling
    Ukropec, Jon
    Vermeulen, Jessica
    de Boer, Carla
    Hoehn, Daniela
    Lin, Thomas S.
    Richardson, Paul G.
    BLOOD, 2020, 136 (08) : 936 - 945
  • [10] Real-World Data on the Daratumumab Plus Bortezomib, Thalidomide and Dexamethasone Followed by Lenalidomide Maintenance for Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
    Crusoe, Edvan de Queiroz
    Ribeiro, Glaciano
    Moura, Fernanda
    Costa, Abel
    Aranha, Milton
    Bittencourt, Rosane
    Ribeiro, Eduardo
    Neto, Jorge
    Cunha, Rafael
    Mattos, Ederson
    Braga, Walter
    Lima, Juliana Souza
    Gusmao, Breno
    Lopes, Danielle Ovigli
    Berg, Luiza
    Souto, Joao
    Maiolino, Angelo
    Hungria, Vania T. M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S223 - S223
12345